Tangeretin (Polymethoxylated Flavone · Cardiovascular · Neuroprotective)

Compound	Tangeretin
Chemical class	Polyphenol — Polymethoxylated Flavone (PMF)
CAS	481-53-8
Primary source	Citrus reticulata (tangerine/mandarin peel)
Key applications	Cardiovascular, anti-inflammatory, neuroprotective
Claim strength	Moderate
Typical form	PMF-standardised citrus peel extract; isolate

Name origin: From tangerine (Citrus reticulata), the primary commercial source. Tangeretin belongs to the polymethoxylated flavone (PMF) subclass, defined by multiple methoxy groups replacing hydroxyls on the flavone scaffold. Traditional use: Citrus peel (chen pi, triphala components) preparations have long use in Traditional Chinese Medicine and Ayurveda for digestive, cardiovascular, and anti-inflammatory indications. PMFs including tangeretin are considered key contributors to the bioactivity of dried citrus peel. Research trajectory: Tangeretin has a moderate evidence base covering lipid modulation, anti-inflammatory signalling, and neuroprotection; it has been investigated in human subjects as part of PMF-containing citrus extracts. Commercial source: Available in PMF-standardised citrus peel extracts; some suppliers offer tangeretin isolate (≥95% HPLC).

---

Evidence for Tangeretin Applications

Lipid modulation and cardiovascular support: Animal feeding studies show tangeretin reduces LDL-C and triglycerides while increasing HDL-C, with mechanisms involving PPAR-α activation and hepatic lipid gene regulation. Human pilot data from PMF-containing citrus extracts support lipid-lowering trends, though tangeretin-specific attribution requires controlled trials. Claim strength: Moderate.

Anti-inflammatory signalling: Tangeretin suppresses NF-κB, COX-2, and iNOS across multiple inflammation models. Its PMF structure confers better membrane permeability than glycoside flavonoids, enabling intracellular target engagement. In vivo anti-inflammatory efficacy is documented in rodent models of arthritis and colitis. Claim strength: Moderate.

Neuroprotective activity: Tangeretin crosses the blood-brain barrier more readily than hydrophilic flavonoids. In vitro and animal studies show inhibition of neuroinflammation (microglial activation), protection against dopaminergic neuron loss in Parkinson models, and cognitive function preservation in aged animals. Claim strength: Emerging (human data absent).

---

Dosage & Formulator Specification

Human clinical data for tangeretin is limited to PMF-blend contexts. Estimated effective doses from citrus peel extract studies: 100–250 mg/day of a PMF-standardised extract (containing tangeretin + nobiletin + sinensetin). Isolated tangeretin dose equivalents are not established.

PMF specification: standardise to minimum 20% total polymethoxylated flavones (HPLC), with tangeretin and nobiletin as co-primary markers. Some specialised suppliers offer 40–50% PMF extracts for higher-potency formulations.

PMFs have superior lipophilicity versus hydroxylated flavonoids (logP tangeretin ~4.2), giving better passive membrane permeability. Lipid-based soft gels or phytosomes are preferred delivery formats. Thermostable to 100°C; suitable for hot-fill beverage applications.

---

Frequently Asked Questions — Tangeretin

What distinguishes PMFs like tangeretin from standard citrus flavonoids?
Polymethoxylated flavones have their hydroxyl groups replaced by methoxy groups, dramatically increasing lipophilicity and passive membrane permeability. This makes them more bioavailable and able to reach intracellular and CNS targets more readily than glycoside counterparts like hesperidin or naringin.

Is tangeretin or nobiletin the better PMF for formulation?
Both are typically co-present in PMF extracts. Tangeretin has stronger evidence for neuroprotective activity; nobiletin has stronger cardiovascular and metabolic data. Specifying a standardised PMF extract delivers both, which may offer broader formulation positioning.

Does tangeretin affect cytochrome P450 enzymes?
PMFs including tangeretin are mild CYP inhibitors in vitro, particularly CYP1A2 and CYP3A4. At typical supplement doses from citrus extract, clinically significant drug interactions are considered unlikely based on current data, but formulators targeting polypharmacy populations should note this.

Can tangeretin be labelled as “citrus extract” on a supplement panel?
Yes, if the source is declared as citrus peel extract standardised to PMF content, with tangeretin listed as the primary constituent marker. This is the most common commercial positioning.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery